Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Net Cash Flow (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Net Cash Flow for 7 consecutive years, with -$48.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 472.94% to -$48.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$25.7 million through Dec 2025, down 423.65% year-over-year, with the annual reading at -$25.7 million for FY2025, 423.65% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$48.3 million at Pliant Therapeutics, down from $6.9 million in the prior quarter.
  • The five-year high for Net Cash Flow was $68.8 million in Q1 2023, with the low at -$48.3 million in Q4 2025.
  • Average Net Cash Flow over 5 years is -$197750.0, with a median of -$416500.0 recorded in 2021.
  • The sharpest move saw Net Cash Flow tumbled 30249.21% in 2022, then surged 997.66% in 2025.
  • Over 5 years, Net Cash Flow stood at $6.4 million in 2021, then crashed by 269.93% to -$10.9 million in 2022, then soared by 164.37% to $7.0 million in 2023, then tumbled by 219.75% to -$8.4 million in 2024, then plummeted by 472.94% to -$48.3 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$48.3 million, $6.9 million, and -$5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.